WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for dome ...

Repligen (RGEN) shares ended the last trading session 4.4% higher at $125.32. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 24.4% loss over the past four weeks. Earlier this month, the company announced that it has promoted Olivier Loeillot, its current chief commercial officer (CCO), as its new president and chief executive officer (CEO), effective from Sep 1, 2024. This might have driven the share price rally. ...

文章核心观点 - 公司宣布现任首席商务官Olivier Loeillot将于2024年9月1日起接任公司新任总裁兼首席执行官[1][2][3] - 现任CEO Tony J. Hunt将于2024年9月1日起转任执行董事长[2] - 公司股价在该消息公布后下跌11.9%[2] 公司概况 - Olivier Loeillot此前曾在GE Healthcare Life Sciences和Cytiva(Danaher公司)担任高级职位,并在Lonza任职[3] - Tony J. Hunt自2015年5月起担任公司CEO,在其领导下公司通过创新产品开发、并购等实现了行业以上的增长[4][5] - 公司近几个季度收入有所下滑,主要是由于缺乏新冠相关收入,以及蛋白业务收入下降[6][7][8] 未来展望 - 公司预计2024年上半年收入将好于2023年下半年[7] - 2024年下半年公司预计将实现强劲的环比和同比增长,得益于新产品的推出[8] - 新任CEO如何应对公司当前的挑战并推动公司实现同比增长仍有待观察[9]

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. L ...

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. L ...

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences. William Blair’s 44th Annual Growth Stock Conference being held in Chicago from June 4 – 6, 2024. Tony J. Hunt, Chief Executive Officer, is scheduled to present a company overview on June 5 at 12:00 p.m. CT. Jefferies’ Global Healthcare Conference being held in New Yor ...

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June investor conferences. William Blair’s 44th Annual Growth Stock Conference being held in Chicago from June 4 – 6, 2024. Tony J. Hunt, Chief Executive Officer, is scheduled to present a company overview on June 5 at 12:00 p.m. CT. Jefferies’ Global Healthcare Conference being held in New Yor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (cid:0) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to___________ Commission File Number 000-14656 REPLIGEN CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 04-2729386 (S ...

Repligen Corporation (NASDAQ:RGEN) Q1 2024 Results Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Sondra Newman - Head of Investor Relations Anthony Hunt - Chief Executive Officer Jason Garland - Chief Financial Officer Olivier Loeillot - President and Chief Commercial Officer Conference Call Participants Rachel Vatnsdal - J.P. Morgan Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Dan Arias - Stifel Conor McNamara - RBC Capital Markets Matt Larew - William Blair & Compan ...

Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results • Reports first quarter revenue of $151 million • Increased new modalities revenue by 16% year-over-year • Increased Filtration (non-COVID) revenue by 12% year-over-year • Achieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 1, 2024 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadershi ...